Safety Data and Beneficial Effects of the Combined Oral Contraceptive Ethinylestradiol 0.03 mg/Chlormadinone Acetate 2 mg (Belara®)A 13-Cycle Observational Study in Routine Clinical Practice

被引：0

作者：

Daphnee S. Pushparajah

Petra Röhm

Kornelia Höschen

Dagmar Albers

Christina Nowack

机构：

[1] Grünenthal GmbH,Department of Science

[2] Grünenthal GmbH,Department of Statistics

[3] Grünenthal GmbH,Department of Clinical Operations

[4] Grünenthal GmbH,undefined

来源：

Clinical Drug Investigation | 2011年 / 31卷

关键词：

Acne; Combine Oral Contraceptive; Premenstrual Syndrome; Breast Tenderness; Breakthrough Bleeding;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Background: The monophasic hormonal combined oral contraceptive (COC) ethinylestradiol (EE) 0.03 mg/chlormadinone acetate (CMA) 2 mg (Belara®) has been shown to have good long-term efficacy and tolerability.

引用

页码：121 / 134

页数：13

共 2 条

[1] Contraceptive Efficacy and Tolerability of Chlormadinone Acetate 2mg/ Ethinylestradiol 0.03mg (Belara®)Results of a Post-Marketing Surveillance Study
G. Schramm
D. Steffens
Clinical Drug Investigation, 2002, 22 : 221 - 231
[2] Extended Cycles with the Combined Oral Contraceptive Chlormadinone Acetate 2 mg/Ethinylestradiol 0.03 mgPooled Analysis of Data from Three Large-Scale, Non-Interventional, Observational Studies
Gunther Göretzlehner
Susanne Waldmann-Rex
Georg A.K. Schramm
Clinical Drug Investigation, 2011, 31 : 269 - 277

← 1 →